Anti-EGFR monoclonal antibody

Phase 2Small molecule

DDragonboat Biopharmaceutical Company Limited

Anti-EGFR monoclonal antibody is one of 8 small molecule programs targeting Advanced Refractory Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Refractory Solid TumorsNot yet recruiting

Advanced Refractory Solid TumorsPhase 2

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Advanced Refractory Solid Tumors

#DrugCompanyPhaseTrials

Pemazyre

Incyte

Phase 1

1 2

GM-CSF

YY-mAbs Therapeutics

Phase 2

3 3

Pucotenlimab

SSun Yat-sen University

Phase 2

1 4

Becotatug Vedotin

FFudan University

Phase 2

1 5

Antibody-Drug Conjugate

MMBrace Therapeutics

Phase 2

1 6

Gilotrif

Boehringer Ingelheim

Phase 1

1 7

PD-L1 Inhibitor

BBuzzard Pharmaceuticals

Phase 2

1 8

Anti-EGFR monoclonal antibody

DDragonboat Biopharmaceutical Company Limited

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Advanced Refractory Solid Tumors

NCT07327411

Clinical

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma2 trials

Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma

Unknown status·SSinocelltech Ltd.·Phase 2·NCT03713372·40 enrolled

SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma

Unknown status·SShi Yuankai·Phase 2·NCT03744208·30 enrolled

Concurrent Chemoradiotherapy1 trial

Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy

Unknown status·FFudan University·Phase 2·NCT04508829·52 enrolled

Advanced Refractory Solid Tumors1 trial

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Not yet recruiting·SSecond Affiliated Hospital of Soochow University·Phase 2·NCT07327411·40 enrolled

Colorectal Cancer1 trial

A Preliminary Clinical Study on the Pharmacokinetics and Safety of Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1) in Patients With Advanced Colorectal Cancer or Head and Neck Squamous Cell Carcinoma

Completed·DDragonboat Biopharmaceutical Company Limited·Phase 1·NCT03491709·18 enrolled

Unspecified1 trial

Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1) to Healthy Volunteers Compared to Erbitux

Completed·DDragonboat Biopharmaceutical Company Limited·Phase 1·NCT03881787·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Anti-EGFR monoclonal antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-EGFR monoclonal antibody compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-EGFR monoclonal antibody. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dragonboat Biopharmaceutical Company Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDragonboat Biopharmaceutical Company Limited

Anti-EGFR monoclonal antibody

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma2 trials

Concurrent Chemoradiotherapy1 trial

Advanced Refractory Solid Tumors1 trial

Colorectal Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News